What's in Biocon Biologics Inc.'s pipeline?

Biocon Biologics Inc. has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Biocon Biologics Inc.'s portfolio?

Top competitors by shared drug class: AMGEN INC, CELLTRION, Roche, SANDOZ INC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/biocon-biologics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Biocon Biologics Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biocon Biologics Inc. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
YESAFILI	AFLIBERCEPT-JBVF	marketed			Other
JOBEVNE	BEVACIZUMAB-NWGD	marketed	Vascular Endothelial Growth Factor Inhibitor [EPC]		Other

Therapeutic area mix

Other · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AMGEN INC · 1 shared drug class
CELLTRION · 1 shared drug class
Roche · 1 shared drug class
SANDOZ INC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Biocon Biologics Inc.:

Cite this brief

Drug Landscape (2026). Biocon Biologics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biocon-biologics-inc. Accessed 2026-05-17.